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ABSTRACT
The extranodal extension (ENE) of nodal metastasis is
the extension of neoplastic cells through the nodal
capsule into the perinodal adipose tissue. This
histological feature has recently been indicated as an
important prognostic factor in different types of
malignancies; in this manuscript, we aim at deﬁning its
role in the prognosis of oesophageal cancer with the
tool of meta-analysis. Two independent authors searched
SCOPUS and PubMed until 31 August 2015 without
language restrictions. The studies with available data
about prognostic parameters in subjects with
oesophageal cancer, comparing patients with the
presence of ENE (ENE+) versus only intranodal extension
(ENE−), were considered as eligible. Data were
summarised using risk ratios (RRs) for number of deaths/
recurrences and HRs together with 95% CIs for time-
dependent risk related to ENE+, adjusted for potential
confounders. Fourteen studies were selected; they
followed-up 1437 patients with oesophageal cancer for
a median follow-up of 39.4 months. The presence of
ENE was associated with a signiﬁcantly increased risk of
all-cause mortality (RR=1.33; 95% CI 1.18 to 1.50,
p<0.0001, I2=49%; HR=2.72, 95% CI 2.03 to 3.64,
p<0.0001, I2=0%), cancer-speciﬁc mortality (RR=1.35;
95% CI 1.14 to 1.59, p=0.001, I2=57%; HR=1.97,
95% CI 1.41 to 2.75, p<0.0001, I2=41%) and of risk
of recurrence (RR=1.50, 95% CI 1.20 to 1.88,
p<0.0001, I2=9%; HR=2.27, 95% CI 1.72 to 2.90,
p<0.0001, I2=0%). On the basis of these results, in
oesophageal cancer, ENE should be considered from the
gross sampling to the pathology report, and in future
oncological staging system.
INTRODUCTION
Upper gastrointestinal malignancies are common
and the incidence and mortality is second only to
lung cancer.1 2 Surgical resection, with or without
chemoradiation, represents the gold standard of
curative treatment for oesophageal cancer.
Advances in perioperative techniques, staging
methods and surgical management have clearly
improved operative mortality and morbidity.2
However, despite improvements in diagnostic and
therapeutic strategies, the prognosis of such
patients remains poor. The prognosis of this cancer,
indeed, seems to mainly depend on clinical features
(eg, performance status), tumour status (eg, tumour
node metastasis system—TNM), extent of surgical
resection and response to chemoradiotherapy.1–5
Oesophageal cancer is classically staged using the
TNM staging system, in which the N category is subdi-
vided in N0, N1, N2 and N3 only on the basis of the
number of metastatic lymph nodes.6 The histological
features of lymph node metastasis have received no
attention. Particularly, the extranodal extension (ENE)
of nodal metastasis, that is the extension of tumour
cells through the nodal capsule into the perinodal
adipose tissue (ﬁgure 1), has recently emerged as an
important prognostic factor in several types of malig-
nancies.7–10 Furthermore, a previous systematic review
with a last search date of almost a decade old,11 sug-
gested that ENE should be considered as a prognostic
factor in all the gastrointestinal malignancies.
Although this review indicated ENE to be a potential
prognostic factor for this cancer, the small number of
the studies included encourages further research about
the possible prognostic role of ENE in this cancer.11
Moreover, no formal meta-analysis currently exists on
this ﬁeld, but could be of importance for having a
better evidence of the association between ENE and
poor prognosis in oesophageal cancer.
Since several new studies in the last years have
investigated this issue and the last review date was
over a decade old, we aimed to weight and clarify
the prognostic role of ENE in patients with lymph
node positive oesophageal cancer with the ﬁrst
meta-analysis on this topic.
METHODS
This systematic review adhered to the Meta-analysis
Of Observational Studies in Epidemiology guidelines
and Preferred Reporting Items for Systematic
Reviews andMeta-Analyses (PRISMA) statement,12 13
following a predetermined protocol.
Inclusion and exclusion criteria
Studies were considered eligible for inclusion if they
satisfy the following criteria: (1) retrospective/pro-
spective, observational cohort studies, (2) contained a
comparison of prognostic factors, among N+
patients, between ENE+ versus ENE−, (3) diagnosis
of cancer of oesophagus±gastro-oesophageal junc-
tion, (4) contained data about the incidence of mor-
tality or recurrence of disease, (5) were published in a
peer review journal or published abstract.
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Exclusion criteria were: (1) no presence of cancer, (2) no data
about prognostic parameters in the title/abstract, (3) comparison
between ENE+ versus no lymph nodes metastases (N0), (4)
diagnosis of non-epithelial malignancies (ie, lymphomas), (5)
diagnosis only of gastro-oesophageal junction (no data about
oesophagus) and (6) in vitro or animal studies. We considered
articles written in any language.
Data sources and literature search strategy
Two investigators (CL and NV) independently searched PubMed
and SCOPUS until 31 August 2015. The search terms used in
PubMed included combinations of the following keywords:
((extracapsular OR pericapsular OR extranodal OR perilymph-
atic OR perinodal OR ‘extra capsular’ OR ‘peri-capsular’ OR
‘extra nodal’ OR ‘peri lymphatic’ OR ‘peri nodal’ OR ‘extra-
capsular’ OR peri-capsular OR ‘extra-nodal’ OR ‘peri-lymphatic’
OR ‘peri-nodal’) AND (esophagus OR oesophagus OR esopha-
geal OR oesophageal OR junction OR junctional) AND (mortal-
ity OR mortalities OR fatality OR fatalities OR death* OR
survival OR prognosis OR ‘hazard ratio’ OR HR OR ‘relative
risk’ OR RR OR prognosis OR progression OR recurrence)). A
similar search was repeated in SCOPUS. We considered also the
reference lists of all included articles and of all previous related
reviews.11
Study selection
Following the searches as outlined above, after removal of dupli-
cates (in the cases of same/similar cohort of patients in different
paper, we selected the largest, the most comprehensive one and/
or the most recent one), two reviewers (MS and GS) independ-
ently screened titles and abstracts of all potentially eligible arti-
cles. The two authors applied the criteria of eligibility,
considered the full texts and a ﬁnal list of included articles was
reached through consensus with a third author (BS) if necessary.
Data extraction
Two authors were involved in data extraction in a predeter-
mined database. One author (AN) extracted data from the
included articles and a second independent author (CL)
validated the data extraction. For each article, we extracted
information about authors, year of publication, country, location
of cancer, exclusion criteria, histotype, type number of adjust-
ments in survival analyses and duration of mean follow-up.
Moreover, number of females, T stage, tumour grading, number
of patients with metastatic lymph nodes, age were extracting by
ENE status (see online supplementary table S1).
Outcomes
The primary outcomes were number of deaths independently
from all the causes, that is, all-cause mortality (ACM), number
of deaths due to cancer, that is, cancer-speciﬁc mortality (CSM)
and number of recurrences after treatment during follow-up
period in those with ENE+ versus ENE−, that is, risk of recur-
rence (ROR). Secondary outcomes were HRs, adjusted for the
maximum number of confounders available, about the same
issues, taking those with ENE− as reference. All these outcomes
were considered at 5 years of follow-up.
Assessment of study quality
The Newcastle-Ottawa Scale (NOS) was used to evaluate study
quality.14 The NOS provides an assessment of the methodo-
logical quality of non-randomised trials and its content validity
and reliability have been already established.12 Included studies
are judged on eight items across three key areas: selection of the
participants, comparability of the participants and outcomes.
Two authors (CL and NV) completed the NOS and each study
receives an overall score for methodological quality of up to
nine points with a score of ≤5 (out of nine) indicating high risk
of bias (see online supplementary tables S2 and S3).14
Data synthesis and statistical analysis
All analyses were conducted using Comprehensive Meta-Analysis
3. In our primary analyses, pooled risk ratios (RRs) and 95% CIs
of ACM, CSM and ROR between ENE+ versus ENE− were cal-
culated using DerSimonian-Laird random-effects models.15 In
secondary analyses, pooled, HRs with 95% CIs adjusted for the
maximum number of covariates available in the articles, were
also calculated for providing additional information if the rela-
tionship between ENE status and outcomes was inﬂuenced by
potential confounders. Heterogeneity across studies was assessed
by the I2 metric and χ2 statistics.16 In the presence of signiﬁcant
heterogeneity (indicated by I2≥50% and/or p<0.05) and for out-
comes having at least four studies, we planned to conduct a series
of meta-regression analyses according to ENE status and each of
prognostic parameters considered. However, since the outcomes
with at least four studies resulted poorly heterogeneous, we
made only a meta-regression analysis for the adjusted HRs for
ACM taking as moderator the number of adjustments.
Finally, we investigated publication bias for our primary
meta-analysis with a visual inspection of funnel plots and with
the Begg–Mazumdar Kendall’s τ and Egger bias test.17 18
Moreover, in the presence of publication bias for the main ana-
lyses, we performed a trim and ﬁll adjusted analysis to remove
the most extreme small studies from the positive side of the
funnel plot, recalculating the effect size at each iteration, until
the funnel plot was symmetric about the (new) effect size.19
RESULTS
Search results
Altogether, 164 non-duplicated articles were identiﬁed through
the literature search. After excluding 137 articles based on title/
abstract review, 27 articles were retrieved for full text review
and, following the application of the inclusion criteria, 14
Figure 1 A classic example of extranodal extension of nodal
metastasis in a case of oesophageal adenocarcinoma (10× original
magniﬁcation). The marginal zone of a metastatic lymph node is totally
occupied by a metastasis, which has broken the nodal capsule to
massively inﬁltrate the perinodal adipose tissue (only a small portion of
residue lymphoid tissue is present).
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unique articles resulted as eligible for this meta-analysis (see
online supplementary ﬁgure S1).20–33
Study and patient characteristics
The studies were conducted in Europe (eight studies,
57.1%),21 22 24–28 30 in Asia (ﬁve studies, 35.7%)20 23 29 31 32
or in Australia (one study, 7.2%),33 with no studies identiﬁed in
America. Globally, 1437 patients (745 ENE+ and 692 ENE−),
with a median follow-up of 39.4 months, were included in this
meta-analysis. Eleven studies speciﬁcally investigated oesopha-
geal cancer only,20–23 26 27 29–33 while three studies considered
together cancers of oesophagus and gastro-oesophageal junc-
tion.24 25 28 About the histotype, three studies are focused on
oesophageal squamous cell carcinoma (SCC),20 23 31 ﬁve on
oesophageal AC,21 24 25 28 30 while ﬁve considered together
these tumour subtypes,22 26 27 29 32 sometimes without a spe-
ciﬁc separation of the data.29 32
The median NOS score was ﬁve points (range: 5–8) with ﬁve
studies at possible high risk of bias for quality (ie, NOS score
≤5) (see online supplementary tables S1 and S2).
Nine out of 14 studies assessed ENE with a classic deﬁn-
ition,20–25 28 30 33 that is the extension of lymph node meta-
static cells through the nodal capsule into the perinodal fatty
tissue, with,22 30 33 or without,20 21 23–25 28 speciﬁc details
about capsule inﬁltration. The remaining ﬁve studies used alter-
native deﬁnitions of ENE.26 27 29 31 32 Particularly, in the two
studies by Metzger et al,26 27 and in the one by Sakai et al,31
ENE is deﬁned as metastatic cancer extending through the
nodal capsule into the perinodal fatty tissue, but deposits of
metastatic cancer cells without a recognisable lymph node were
also considered as ENE, unless these deposits were associated
with perineural and/or vessel involvement. Furthermore, for
Nakano et al,29 ENE is the presence of cancer cells in the con-
nective tissues around the removed nodes detected by histo-
logical examination, while for Tachikawa et al,32 it is deﬁned as
a metastasis apparently penetrating the capsule or accompanied
by carcinomatous nodules such as extracapsular vessel invasion,
excluding carcinomatous nodules of the oesophageal wall.
Only three studies reported the use of preoperative therapy
(neoadjuvant chemotherapy and/or radiotherapy), but we
cannot speciﬁcally obtain the total number of N1 (ENE− vs
ENE+) patients from these three studies.22 27 33
There were very few studies (three studies on ENE+ patients
and two on ENE−) that reported complete clinical–pathological
data, divided between ENE+ and ENE−, to make a reliable
comparison; however, where provided, there is not a clear dif-
ferences in such parameters, like TNM status at the time of
diagnosis or tumour grading, between ENE+ and ENE−
patients.
Furthermore, ﬁve studies reported data about the total
number of resected and identiﬁed lymph nodes,22 25–28 of
which the mean number per patients was 31.7. Two studies
reported this kind of data also divided on the basis of the pres-
ence of ENE;25 28 particularly, in these studies the mean
number of lymph nodes was 35.1 in ENE+ patients versus 33.9
in ENE− patients, without a statistically signiﬁcant difference.
RRs on ACM, CSM and ROR
Pooling data from eight studies reporting data on
ACM,23 26 27 29–33 86.2% with ENE+ were dead versus 64.5%
with ENE−, leading to a signiﬁcant increased risk of mortality
for all cause (RR=1.33; 95% CI 1.18 to 1.50, p<0.0001,
I2=49%) (table 1, ﬁgure 2).
Moreover, CSM was reported in three studies,24 25 28 and
resulted signiﬁcantly higher in ENE+ than ENE− patients
(RR=1.35; 95% CI 1.14 to 1.59, p=0.001, I2=57%) (table 1,
see online supplementary ﬁgure S2).
Lastly, ENE+ was further associated to a signiﬁcant higher
ROR (three studies);20 22 31 69.7% in ENE+ versus 46.5% in
ENE− patients experienced a recurrence, equating to an
RR=1.50 (95% CI 1.20 to 1.88, p<0.0001, I2=9%) (table 1;
see online supplementary ﬁgure S3).
The analysis for identifying a publication bias was possible
only for ACM outcome, since this analysis requires at least four
studies. As shown in the funnel plot of the studies taking as
outcome ACM (see online supplementary ﬁgure S4) there was
an evidence of publication bias, due to a higher proportion of
studies at the right side of the mean (indicating a signiﬁcant
association between ENE+ with reduced ACM). These ﬁndings
were conﬁrmed by the Egger’s test (bias=3.4; 95% CI 0.78 to
1.52, p=0.005) and Begg–Mazumdar test (Kendall’s τ=0.61,
p=0.04). Given the publication bias observed, we calculated the
trim and ﬁll adjusted analysis which demonstrated a pooled RR
of 1.22 (95% CI 1.06 to 1.41) suggesting that the publication
bias for this outcome is unlikely.17
Adjusted HRs on ACM, CSM and ROR
In our secondary analyses, we investigated whether using HRs
(adjusted for the maximum number of the covariates reported
in each study) instead of RRs could inﬂuence our results.
Altogether, the median number of adjustments used was 3
(range: 0–9) (see online supplementary tables S1 and S3).
Table 2 shows the adjusted HRs according to ENE status:
ENE+ was associated to a signiﬁcant poorer prognosis, being
associated with a higher risk of ACM (four studies;21 26 27 31
median number of adjustments=5 (range: 4–7); HR=2.72,
95% CI 2.03 to 3.64, p<0.0001, I2=0%) (see online
supplementary ﬁgure S5), CSM (three studies;24 25 28 median
number of adjustments=4 (range: 2–7); HR=1.97, 95% CI
1.41 to 2.75, p<0.0001, I2=41%) (see online supplementary
ﬁgure S6) and ROR (three studies;21 22 24 median number of
Table 1 Pooled risk ratio estimates for ACM, CSM and ROR according to presence or not of ENE
Parameter
No of
studies
No of events* in
ENE+
No of
ENE+
No of
events*
in ENE−
No of
ENE−
Risk ratio
(95% CI) p Value Heterogeneity
ACM 8 288 334 253 392 1.33 (1.18 to 1.50) <0.0001 τ2=0.01; χ2=13.80, df=7 (p=0.06); I2=49%
CSM 3 319 371 143 223 1.35 (1.14 to 1.59) 0.001 τ2=0.11; χ2=4.67, df=2 (p=0.10); I2=57%
ROR 3 69 99 73 157 1.50 (1.20 to 1.88) <0.0001 τ2=0.06; χ2=2.21, df=2 (p=0.33); I2=9%
*Events stand for death for ACM and CSM, and for recurrence for ROR.
ACM, all-cause mortality; CSM, cancer-specific mortality; ENE, extranodal extension; ROR, risk of recurrence.
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adjustments=6 (range: 1–7); HR=2.27, 95% CI 1.72 to 2.90,
p<0.0001, I2=0%) (see online supplementary ﬁgure S7).
No publication bias evident using adjusted HRs instead of RR
for ACM (see online supplementary ﬁgure S8) (Egger’s test:
bias=0.97; 95% CI −6.98 to 8.94, p=0.65; Begg–Mazumdar
test: Kendall’s τ=0.00, p=1.00).
Meta-regression analysis
Among the outcomes investigated, only RR for CSM showed a
high heterogeneity (I2=57%). However, this outcome included
only three studies, thus precluding a meta-regression analysis.
Since it is conceivable that the strength of the association
between ENE+ and reduced ACM in adjusted HRs estimates
may depend on the number of adjustments, we conducted a
meta-regression analysis between these two estimates that,
however, did not show any signiﬁcant association (β=−0.04;
95% CI −0.45 to 0.37, p=0.86, R2=0%).
DISCUSSION
In this study, we analysed 14 observational studies involving
1437 patients affected by oesophageal cancer with metastatic
lymph nodes. Of them, 745 presented ENE+, while 692
showed only intranodal metastasis. Our ﬁndings suggest that the
presence of ENE is strongly associated to a poor prognosis in all
the most important prognostic indexes, namely ACM, CSM and
ROR. Although a potential publication bias was evident, it
seems that the relationship was evident after the trim and ﬁll
adjusted analysis. Moreover, the association between ENE and
poor prognosis was also maintained considering HR adjusted
for potential confounders. Furthermore, reinforcing the robust-
ness of our ﬁndings, the vast majority of prognostic outcomes
were not characterised by a signiﬁcant heterogeneity.
It is noteworthy that in three studies all the node-positive
patients with ENE died within 5 years,23 30 32 highlighting the
important prognostic signiﬁcance of this morphologic aspect.
There are several potential implications derived from this study.
The ﬁrst regards the surgical pathology approach and particu-
larly the gross sampling. Indeed, on the basis of the shown
importance of ENE in oesophageal cancer, and knowing that
ENE can be very focal in a metastatic lymph node, a fundamen-
tal consequence is that all the lymph nodes with their surround-
ing adipose tissue have to be completely included, and not
simply isolated from the fatty tissue. The most common
approach for surgical pathologists during grossing starts with
the manual isolation of lymph nodes; if there is an enlarged
lymph node with a metastatic aspect, the pathologists often start
to include only a portion of this, because the only thing
required is the demonstration of a metastasis, and also because
of an economic reason. However, on the basis of this systematic
review and meta-analysis, a complete inclusion of all the lymph
nodes, even if very large, and also of the perinodal adipose
tissue is recommended.
There is not a statistically signiﬁcant difference between the total
number of resected and identiﬁed lymph nodes and the detection
of ENE. However, some authors indicated that the number of
lymph nodes with ENE was signiﬁcantly correlated with the
number of positive nodes and lymph node ratio (ie, number of
positive lymph nodes/total number of lymph nodes).22 26 27 31
Particularly, ENE was seen more often if the number of positive
nodes and the lymph node ratio were higher, highlighting the role
of ENE as a marker of poor prognosis.
Notably, the prevalence of ENE resulted more frequently in AC
than in SCC. Metzger et al presented separately data between these
two subtypes, showing a prevalence of ENE of 66% in AC and of
35% in SCC.26 Similar results, with a predominance of ENE in
AC, have been shown by Thompson et al.33 For SCC, Tachikawa
et al found a prevalence of ENE in 39% of node-positive patients,
and Nakano et al in 41%.29 32 However, both Nakano et al and
Tachikawa et al considered also tumour cells found in the perinodal
soft tissue as ENE, and this may explain the slightly higher frequen-
cies than Metzger et al. At the same time, Lerut et al and Lagarde
et al analysed relatively uniform cohorts of patients with AC,
Figure 2 Forest plot for relative risk of overall survival. ENE, extranodal extension.
Table 2 Pooled risk ratio estimates for adjusted HRs for overall
and disease free survival according to presence or not of ENE
Parameter
No of
studies HRs (95% CI) p Value Heterogeneity
ACM 4 2.72 (2.03 to 3.64) <0.0001 τ2=0.00; χ2=0.24, df=3
(p=0.97); I2=0%
CSM 3 1.97 (1.41 to 2.75) <0.0001 τ2=0.04; χ2=3.43, df=2
(p=0.18); I2=41%
ROR 3 2.27 (1.72 to 2.90) <0.0001 τ2=0.00; χ2=1.48, df=2
(p=0.48); I2=0%
ACM, all-cause mortality; CSM, cancer-specific mortality; ENE, extranodal extension;
ROR, risk of recurrence.
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producing similar results about this tumour histotype, with a preva-
lence of ENE of 63% and 66%, respectively.24 25 Despite of a reli-
able importance of ENE in both AC and SCC, further studies are
needed to investigate more in depth and separately the role of ENE
in inﬂuencing the prognosis in these different tumour types.
Other considerations can be made about neoadjuvant chemo-
therapy (CHT). Interestingly, Metzger et al indicated that
neoadjuvant therapy did not reduce the occurrence of ENE,
with similar percentages in a cohort with and in a second
without neoadjuvant CHT.27 These results were substantially
conﬁrmed also by Thompson et al.33 The conservation of ENE
after neo-adjuvant treatment increases its importance, since this
prognostic parameter can be assessed also in post-CHT speci-
mens, with the same value of a marker of poor prognosis.
Furthermore, another aspect that has to be addressed is a
standard deﬁnition of ENE, since this parameter, on the basis of
this meta-analysis, should be considered by the staging systems
and reported in the ﬁnal pathology report. Nine out of 14
studies assessed ENE classically, that is, as the extension of meta-
static cells through the nodal capsule into the perinodal adipose
tissue.20–25 28 30 33 Five studies,26 27 29 31 32 however, used
alternative deﬁnitions of ENE. Particularly, also deposits of
metastatic cancer cells without a recognisable lymph node,
unless these deposits were associated with perineural and/or
vessel involvement,26 27 31 or the presence of cancer cells in the
connective tissues around the removed nodes,32 were considered
as part of ENE deﬁnition. Using these deﬁnitions, also free
tumour deposits could be included in our meta-analysis, intro-
ducing a possible bias. However, the results of our meta-analysis
seem to be robust (as shown by low heterogeneity by the out-
comes included) to be affected signiﬁcantly by this issue, that
moreover concerns only four out of 14 studies. Furthermore,
this point highlights the importance of looking for a standard
deﬁnition of ENE. We recommend considering true ENE only a
non-debatable ENE, that is demonstrated histologically and
characterised by a structural rupture of the lymph node capsule
by the metastasis. Neoplastic emboli, free tumour cells deposits
in soft tissue and metastasis in the marginal sinus and should
not be considered as true ENE. Notably, the presence of tumour
cells in the adipose tissue is recognised as associated to a poor
prognosis: for example, in the TNM staging system for colorec-
tal cancer, the free tumour deposits in the adipose tissue are
recognised as important prognostic parameters, constituting a
speciﬁc subcategory in N group, named N1c.6 8 Furthermore,
ENE has also been taken into account in the last staging systems
of squamous cell carcinoma of the vulva, playing an important
and adverse prognostic role.10 On the basis of this
meta-analysis, and if further studies and/or nomograms will
conﬁrm our results, the presence of ENE should be included in
the staging system also for oesophageal cancer.
Considering implications for therapy pointed out by this
meta-analysis, it has to be reported that patients with ENE in
pancreatic cancer seem to beneﬁt from adjuvant chemoradia-
tion, but not from chemotherapy alone.7 34 This aspect has to
be investigated by future studies, and could address particular
therapeutic approaches if conﬁrmed for oesophageal cancers.
While the results of this meta-analysis are clear and novel, we
have also to consider some limitations of our paper. First, data
about other comorbidities (like cardiovascular diseases) were
not consistently reported by the primary studies, but it is known
that they have an important role in the prognosis also of
patients with cancer. Second, while the evidence for ACM
seems to be exhaustive since it includes eight studies in both not
adjusted and adjusted analyses, the evidence about CSM and
ROR is more limited. This issue is probably due to the fact that
oesophageal cancer has one of the most lethality among all
cancers and so the possibility of recurrence is limited and ACM
is probably similar to CSM. However, future research is needed
about the role of ENE for these speciﬁc outcomes.
In conclusion, our results indicate that ENE seems to be strongly
associated with a poorer prognosis in oesophageal cancer, also
independent of potential confounders. This condition is present in
a remarkable proportion of the patients affected by such malig-
nancy. Therefore, its consideration becomes fundamental from the
gross sampling to the histopathological evaluation and the onco-
logical staging. A ﬁnal consideration regards the recent develop-
ment of techniques of DNA sequencing: it has been already
proposed an integration of the pathology report with a complete
molecular characterisation of cancer;35 36 however, before this, all
the prognostic roles of the pure morphological features and of the
histological aspects, as ENE, should be clariﬁed.
Take home messages
▸ ENE is important in inﬂuencing the prognosis of some solid
cancers.
▸ We investigate if ENE may be important also for
oesophageal cancer.
▸ We demonstrate its importance with the tool of meta-
analysis.
▸ Thanks to our results, it should be considered by future
staging system.
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